FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011567397> ?p ?o ?g. }

• W2011567397 endingPage "S37" @default.
• W2011567397 startingPage "S37" @default.
• W2011567397 abstract "Objective The optimal therapeutic opproach for pts with HD-HIV is unknown, In an attempt to improve the results that we obtained in a previous prospective study with EBY without G-CSF (Cancer, 73: 437–44, 1994). in January 1993 we started a second trial consisting of CT, concomitant antiretroviral therapy (AZT or DDI), and G-CSF. Methods Up to October 1995, 27(23M/4F)consecutive previously untreated pts (median age 33, range21–49 years) with HD-HIV were enrolled. Median performence status was 1 (range 1–3). At diagnosis of HD, 7 (26%) of pts had AIDS, 3(11%) ARC, and 17 (63%) were asymptomatic. Eighty-five per cent of pts had B symptoms at HD presentation. Pts received E 70 mg/m2 i.v. on day I, B 10 mg/2i.v. on day 1, V6 mg/m2 i.v. on day 1 and P 40 mg/m2p.o. from day 1 today 5. Courses were repeated every 21 days for six cyclcs. AZT (250 mg x 21/day) or DDI (200 or 300 mg × 2/day), when AZT w previously used, were given orally from the beginning of CT. G-CSF was given at the dose of 5 mcg/kg/day s.e. from day 6 to day 20 in all cyeles. Results Tabled 1Table # pts CD4+at diagnosis Subtype Stage Response DFS entered/evaluable median # (range) MC & LD III & IV OR CR at 2 yrs 27/21 * pts are still on treatment 187 (6–812) 18(66%) 22(82%) 90% 71% 43% * pts are still on treatment Open table in a new tab Toxicity was moderate with grade 3–4 leukopenia and thrombocytopeni in 7 (33%) and in 2 (10%) pts respectively. Fifteen out of 21 pts received AZT and 2 pts received DDI. Only 6 (28%) pts had opportunistic infections (OI), during or after CT (median follow-up. 14 months). No change of CD4+ cell count was seen, being the median number 171/mm3 (2–529) after the end of combined therapy. Six out of 15 (40%) pts who achieved a CR relapsed. Overall, HD progression alone and in assciation with OI was the cause of death in 46% and in 15% of pts respectively. The median survival was 14 months with an actuarial survival rate of 33% at 24 months. Conclusions The combined treatment was feasible. However, although the CR rate obtained was satisfactory, the number of relapsed pts was high and overall median survival was not different from our previous experience or from literature, Taking in consideration the moderate toxicity, we are currently considering higher doses of CT at shorter interval with the support by G-CSF. Supported by A1RC 95 and ISS ‘95. The optimal therapeutic opproach for pts with HD-HIV is unknown, In an attempt to improve the results that we obtained in a previous prospective study with EBY without G-CSF (Cancer, 73: 437–44, 1994). in January 1993 we started a second trial consisting of CT, concomitant antiretroviral therapy (AZT or DDI), and G-CSF. Up to October 1995, 27(23M/4F)consecutive previously untreated pts (median age 33, range21–49 years) with HD-HIV were enrolled. Median performence status was 1 (range 1–3). At diagnosis of HD, 7 (26%) of pts had AIDS, 3(11%) ARC, and 17 (63%) were asymptomatic. Eighty-five per cent of pts had B symptoms at HD presentation. Pts received E 70 mg/m2 i.v. on day I, B 10 mg/2i.v. on day 1, V6 mg/m2 i.v. on day 1 and P 40 mg/m2p.o. from day 1 today 5. Courses were repeated every 21 days for six cyclcs. AZT (250 mg x 21/day) or DDI (200 or 300 mg × 2/day), when AZT w previously used, were given orally from the beginning of CT. G-CSF was given at the dose of 5 mcg/kg/day s.e. from day 6 to day 20 in all cyeles. Toxicity was moderate with grade 3–4 leukopenia and thrombocytopeni in 7 (33%) and in 2 (10%) pts respectively. Fifteen out of 21 pts received AZT and 2 pts received DDI. Only 6 (28%) pts had opportunistic infections (OI), during or after CT (median follow-up. 14 months). No change of CD4+ cell count was seen, being the median number 171/mm3 (2–529) after the end of combined therapy. Six out of 15 (40%) pts who achieved a CR relapsed. Overall, HD progression alone and in assciation with OI was the cause of death in 46% and in 15% of pts respectively. The median survival was 14 months with an actuarial survival rate of 33% at 24 months. The combined treatment was feasible. However, although the CR rate obtained was satisfactory, the number of relapsed pts was high and overall median survival was not different from our previous experience or from literature, Taking in consideration the moderate toxicity, we are currently considering higher doses of CT at shorter interval with the support by G-CSF. Supported by A1RC 95 and ISS ‘95." @default.
• W2011567397 created "2016-06-24" @default.
• W2011567397 creator A5003114419 @default.
• W2011567397 creator A5005665639 @default.
• W2011567397 creator A5021793394 @default.
• W2011567397 creator A5024782995 @default.
• W2011567397 creator A5028848530 @default.
• W2011567397 creator A5038699632 @default.
• W2011567397 creator A5040015241 @default.
• W2011567397 creator A5046311100 @default.
• W2011567397 creator A5050887147 @default.
• W2011567397 creator A5066841951 @default.
• W2011567397 creator A5069200191 @default.
• W2011567397 creator A5073665066 @default.
• W2011567397 date "1996-01-01" @default.
• W2011567397 modified "2023-10-05" @default.
• W2011567397 title "182 P - Epirubicin, bleomycin, vinblastine and prednisone (EBVP) chemotherapy (CT) in combination with antiretroviral therapy and primary use of G-CSF for patients (pts) with hodgkin's disease and HIV infection (HD-HIV)" @default.
• W2011567397 doi "https://doi.org/10.1016/0959-8049(96)84936-7" @default.
• W2011567397 hasPublicationYear "1996" @default.
• W2011567397 type Work @default.
• W2011567397 sameAs 2011567397 @default.
• W2011567397 citedByCount "0" @default.
• W2011567397 crossrefType "journal-article" @default.
• W2011567397 hasAuthorship W2011567397A5003114419 @default.
• W2011567397 hasAuthorship W2011567397A5005665639 @default.
• W2011567397 hasAuthorship W2011567397A5021793394 @default.
• W2011567397 hasAuthorship W2011567397A5024782995 @default.
• W2011567397 hasAuthorship W2011567397A5028848530 @default.
• W2011567397 hasAuthorship W2011567397A5038699632 @default.
• W2011567397 hasAuthorship W2011567397A5040015241 @default.
• W2011567397 hasAuthorship W2011567397A5046311100 @default.
• W2011567397 hasAuthorship W2011567397A5050887147 @default.
• W2011567397 hasAuthorship W2011567397A5066841951 @default.
• W2011567397 hasAuthorship W2011567397A5069200191 @default.
• W2011567397 hasAuthorship W2011567397A5073665066 @default.
• W2011567397 hasConcept C126322002 @default.
• W2011567397 hasConcept C141071460 @default.
• W2011567397 hasConcept C203014093 @default.
• W2011567397 hasConcept C2776694085 @default.
• W2011567397 hasConcept C2776755627 @default.
• W2011567397 hasConcept C2777910003 @default.
• W2011567397 hasConcept C2779127605 @default.
• W2011567397 hasConcept C2779384505 @default.
• W2011567397 hasConcept C2780727368 @default.
• W2011567397 hasConcept C2780835546 @default.
• W2011567397 hasConcept C3013748606 @default.
• W2011567397 hasConcept C71924100 @default.
• W2011567397 hasConcept C90924648 @default.
• W2011567397 hasConceptScore W2011567397C126322002 @default.
• W2011567397 hasConceptScore W2011567397C141071460 @default.
• W2011567397 hasConceptScore W2011567397C203014093 @default.
• W2011567397 hasConceptScore W2011567397C2776694085 @default.
• W2011567397 hasConceptScore W2011567397C2776755627 @default.
• W2011567397 hasConceptScore W2011567397C2777910003 @default.
• W2011567397 hasConceptScore W2011567397C2779127605 @default.
• W2011567397 hasConceptScore W2011567397C2779384505 @default.
• W2011567397 hasConceptScore W2011567397C2780727368 @default.
• W2011567397 hasConceptScore W2011567397C2780835546 @default.
• W2011567397 hasConceptScore W2011567397C3013748606 @default.
• W2011567397 hasConceptScore W2011567397C71924100 @default.
• W2011567397 hasConceptScore W2011567397C90924648 @default.
• W2011567397 hasLocation W20115673971 @default.
• W2011567397 hasOpenAccess W2011567397 @default.
• W2011567397 hasPrimaryLocation W20115673971 @default.
• W2011567397 hasRelatedWork W1987215768 @default.
• W2011567397 hasRelatedWork W1991129960 @default.
• W2011567397 hasRelatedWork W1995188757 @default.
• W2011567397 hasRelatedWork W2007817983 @default.
• W2011567397 hasRelatedWork W2016679923 @default.
• W2011567397 hasRelatedWork W2106653639 @default.
• W2011567397 hasRelatedWork W2116001782 @default.
• W2011567397 hasRelatedWork W2943195325 @default.
• W2011567397 hasRelatedWork W4229900919 @default.
• W2011567397 hasRelatedWork W17604275 @default.
• W2011567397 hasVolume "32" @default.
• W2011567397 isParatext "false" @default.
• W2011567397 isRetracted "false" @default.
• W2011567397 magId "2011567397" @default.
• W2011567397 workType "article" @default.